Trial · Interventional
CompletedPhase 3Registry dataGhrelin - A Possible Opportunity to Improve Appetite
Short name Phase 3
Overview
- Status
- Completed
- Phase
- Phase 3
- Enrollment
- 30 participants (estimated)
- Sponsor
- Göteborg University · Other
- Design
- Randomized · Triple masking
- Countries
1 country
Sweden
- Start
- Oct 2003
- Primary completion
- Jun 2008
- Completion
- Jul 2008
- First posted
- 21 May 2008 (estimated)
- Last update posted
- 21 Aug 2009 (estimated)
- Conditions
- Cancer
Timeline
1 trial · 1 completed
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 3
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.
Interventions
- GhrelinDrug
- GhrelinDrug
Arms2
Active comparator
A, 1
Ghrelin
Active comparator
A, 2
Ghrelin.
Primary outcomes1
Outcomes the sponsor listed as primary.
Food intake
Time frame · June 2008
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
Completed trials do not always post results.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 40 Years up to 80 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.